ShadowBuys

Lobbying disclosures · Lobbying report

AMGN: third_quarter 2026 lobbying report

Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.

Follow AMGN
Became public
Oct 20, 2026, 12:35 PM EDT
Event / period date
Not stated
Collected
Nov 8, 2026, 11:40 AM EST

Why this is connected

Exact legal-name match: AMGEN INC (https://www.sec.gov/Archives/edgar/data/318154/).

Reported lobbying amounts

Income: $50,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/c4133d52-1392-4bed-9803-c3f1a7d421ee/","filing_uuid":"c4133d52-1392-4bed-9803-c3f1a7d421ee","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/c4133d52-1392-4bed-9803-c3f1a7d421ee/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Chelsea J. Mincheff","dt_posted":"2026-10-20T12:35:30-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 Thirteenth Street, NW","registrant_address_2":"Eleventh Floor South","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":5357,"url":"https://lda.gov/api/v1/registrants/5357/","house_registrant_id":31564,"name":"BGR GOVERNMENT AFFAIRS","description":"Lobbying firm","address_1":"601 13th Street, NW","address_2":"11th Floor South","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHELSEA MINCHEFF","contact_telephone":"+1 202-661-6385","dt_updated":"2026-07-30T12:12:37.308899-04:00"},"client":{"id":106211,"url":"https://lda.gov/api/v1/clients/106211/","client_id":63,"name":"AMGEN INC.","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-06-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23860,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"WOOD","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug","new":false},{"lobbyist":{"id":62729,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"ALAN","last_name":"DEL MONTE","suffix":null,"suffix_display":null},"covered_position":"Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee","new":false},{"lobbyist":{"id":65427,"prefix":null,"prefix_display":null,"first_name":"ROBB","nickname":null,"middle_name":null,"last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":"Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes","new":false},{"lobbyist":{"id":67545,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":"Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C","new":false},{"lobbyist":{"id":143823,"prefix":"ms","prefix_display":"MS.","first_name":"REMY","nickname":null,"middle_name":"LEIGH BRIM","last_name":"MASON","suffix":null,"suffix_display":null},"covered_position":"Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz","new":false},{"lobbyist":{"id":121840,"prefix":null,"prefix_display":null,"first_name":"JOEL","nickname":null,"middle_name":"D.","last_name":"BAILEY","suffix":null,"suffix_display":null},"covered_position":"COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall","new":false},{"lobbyist":{"id":146083,"prefix":null,"prefix_display":null,"first_name":"RAGHAV","nickname":null,"middle_name":null,"last_name":"AGGARWAL","suffix":null,"suffix_display":null},"covered_position":"Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior","new":true},{"lobbyist":{"id":148824,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"KELLY","suffix":null,"suffix_display":null},"covered_position":"Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in AMGN

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.